Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.
Edward Wolin, MD
Advertisement
Articles by Edward Wolin, MD
Edward Wolin, MD, discusses the safety profile of 177Lu-dotatate in patients with advanced neuroendocrine tumors.
Advertisement
Latest Updated Articles
Dr. Wolin on the Safety of Lutathera in Advanced NETsPublished: October 2nd 2020 | Updated:
Dr. Wolin on the Treatment Landscape of NETsPublished: October 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5